Liver cancer is one of the most common causes of cancer death in China. As a promising local minimally invasive treatment, the efficacy and safety of yttrium-90 microsphere selective internal radiotherapy has been confirmed by clinical application in the past 20 years, and has been recommended for local treatment of liver malignant tumors by the National Comprehensive Cancer Network (NCCN) and other international guidelines.
Recently, Xi'an International Medical Center Hospital was successfully approved the radiation safety license for the first yttrium-90 microsphere treatment in the northwest, marking the completion and use of the yttrium-90 interventional treatment center built in the nuclear medicine department in accordance with the national radiation safety and radiation diagnosis and treatment regulations.
This means that patients with liver cancer, including primary or metastatic liver cancer, especially those with advanced liver cancer and other unresectable liver tumors, can receive internationally advanced targeted radiotherapy in Xi'an International Medical Center Hospital. It will bring hope and opportunity for more patients with liver cancer to undergo radical treatment, achieve clinical cure and return to normal life.
[What is yttrium-90 microsphere therapy?]
Yttrium-90 microsphere selective internal radiation therapy (abbreviated as 90Y-SIRT), the principle of which is to use a microcatheter to inject the microsphere containing radioactive substance Yttrium 90 into the hepatic artery, and the microsphere reaches the liver tumor site along with the blood flow, through the release β X-rays kill tumors efficiently. Because of its high energy, precise radiation and no damage to the surrounding normal liver tissue, it carries out precise attack on the tumor from inside to outside, and has the reputation of "nuclear weapon" for precise guidance of liver cancer treatment in the industry.
[What are the advantages of yttrium-90 microsphere therapy?]
Both yttrium-90 microsphere therapy and traditional TACE (transcatheter arterial chemoembolization) are used as transcatheter therapy for the treatment of middle and advanced liver cancer. Compared with traditional TACE treatment, yttrium-90 microsphere is a treatment method that relies on the characteristics of tumor blood supply to selectively retain radioactive substances in tumor tissue, release short-distance radiation to kill tumor tissue, and minimize damage to normal tissue. Its advantages include:
① The effect of tumor reduction is significant, and the goal of treatment in descending phase is achieved
Yttrium-90 microsphere therapy has the dual effects of strong tumor contraction and increased residual liver volume. This outstanding advantage also makes it an ideal choice for patients with primary unresectable liver cancer to achieve the stage reduction and transformation treatment. The patients who do not meet the criteria of liver transplantation will be reduced to Milan standard through auxiliary "downgrading treatment", so that the patients who do not meet the criteria of indications will get the opportunity of transplantation.
② Accurate targeted killing of cancer tissue, almost without damage to normal liver tissue
The treatment of yttrium-90 microsphere is mainly through the radiation effect of yttrium-90 microsphere to cause irreversible damage to tumor epithelial cells, matrix and endothelial cells, resulting in tumor necrosis, rather than relying on microembolization to cause tumor tissue ischemia and hypoxia or the killing effect of chemotherapy drugs to inhibit tumor. Therefore, it can almost not damage the surrounding normal liver tissue, achieve the maximum retention of the remaining liver volume, and have a higher success rate in the treatment of depression, longer progression-free survival time, less side effects on human body, and more safety.
③ High rate of complete elimination of lesions, reduced microvascular invasion, and reduced recurrence rate after transplantation
According to clinical data, compared with TACE treatment, yttrium-90 can achieve a high rate of CPN (complete pathological necrosis), effectively reduce microvascular invasion and reduce the recurrence rate of patients after transplantation. Compared with other conventional treatment methods, the 5-year survival rate of patients with advanced liver cancer treated with yttrium-90 microspheres increased to 60%~70%.
④ The treatment period is short, the adverse reactions are few, and the impact on the patient's physical condition is small
Yttrium-90 microsphere treatment has the advantages of accurate treatment, small trauma and slight side effects. Therefore, it can also be used for first-line treatment of elderly patients or patients with liver tumors with poor physical fitness score (PS score).
[Development status of yttrium-90 microsphere therapy at home and abroad]
Yttrium-90 microsphere selective internal radiotherapy was listed in the United States as early as around 2000 and has been widely used in clinical practice. At present, it has treated more than 120000 people in more than 50 countries and regions around the world. Its safety and effectiveness have been fully verified and recommended by mainstream clinical guidelines in the United States, Europe and China.
Yttrium-90 microsphere injection was approved by China National Drug Administration (NMPA) on February 9, 2022 and officially applied in China.
At present, Professor Han Guohong, executive director of the Digestive Hospital of Xi'an International Medical Center, led the establishment of a multidisciplinary, multi-agency and multidisciplinary expert team, and successfully introduced and landed the Yttrium-90 microsphere clinical treatment of liver cancer project in Xi'an. Xi'an International Medical Center has also become one of the few hospitals in the country that can standardize the development of this technology.
[Yttrium-90 microsphere treatment recruitment for liver cancer patients]
Yttrium-90 microsphere therapy, as the main local minimally invasive treatment method, has shown unique efficacy and safety in clinical practice. It can significantly improve the quality of life of patients with advanced liver cancer, and plays an increasingly important role in the treatment of liver cancer, bringing hope for surgery and long-term survival for patients with primary unresectable liver cancer.
The Digestive Hospital of Xi'an International Medical Center is committed to building a standardized, standardized, routine and nationally leading Y90 interventional therapy center according to the requirements of Y90 microspheres for the treatment of unresectable liver tumors. Patients who are willing to receive Yttrium-90 microsphere treatment include: primary liver cancer, metastatic liver cancer (colorectal cancer, neuroendocrine tumor and other unresectable liver tumors)
Contact: Assistant Li, Assistant Yuan, Assistant Wu
Tel: 15802916324, 13359226970, 18966934303
Profile of Professor Han Guohong's team
Han Guohong, currently the executive director of Digestive Hospital of Xi'an International Medical Center Hospital, medical doctor, chief physician, professor and doctoral supervisor. The former director of the Digestive Intervention Department of the Digestive Hospital of Xijing Hospital of the Air Force Military Medical University, and the former leader of the Vascular Intervention Group of the National Digestive Disease Clinical Medical Research Center of Xijing Hospital.
Professor Han Guohong's team has been engaged in liver cancer intervention for more than 30 years, has treated more than 10000 people with liver cancer, and has established the first international individualized prediction and risk stratification model "Six-and-twelve" score for TACE ideal population. It has taken the lead in carrying out interventional targeted and combined immunotherapy for liver cancer, so that more patients can benefit from the treatment mode of 1 1>2 or even 1 1>3. Participated in, designed and led more than 20 clinical trials related to liver cancer at home and abroad, and many research results were published in international authoritative academic journals, and the guidelines for liver cancer of many international societies were rewritten. The research achievements have successively won the Innovation Team Award of the National Science and Technology Progress Award (2016) and the first prize of the Military Science and Technology Progress Award (2017).
In view of his profound achievements in the field of diagnosis and treatment of liver cancer, Professor Han Guohong was elected as a member of the Council of Primary Liver Cancer in Asia Pacific in 2017, and vice chairman of the Professional Committee of Tumor Hepatology of the China Anti-Cancer Association in 2022. He participated in the formulation of the diagnosis and treatment specifications of primary liver cancer of the Health and Health Commission as the deputy leader of the interventional therapy group for 11 consecutive years (2011-2022), and wrote the TACE guide for Chinese hepatocellular carcinoma as the main author, He was awarded the title of the second national famous doctor pageant in 2018 - National famous doctor's excellent demeanor, and was rated Top10dr in the Top 100 Chinese Famous Doctors List for eight consecutive years from 2011 to 2018. In 2020, he ranked the sixth in the academic influence of China's digestive disease field, and the eleventh in the field of digestive disease in China in the past 10 years (2011-2011).